A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
CONCLUSION: This real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression.PMID:38528295 | DOI:10.1007/s10147-024-02492-5 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 26, 2024 Category: Cancer & Oncology Authors: Della Varghese Giovanna I Cruz Colden Johanson Liz Toland Miguel Miranda Eleanor C Faherty David Harland Henry G Kaplan Source Type: research
Challenges in Obtaining and Seeking Information Among Breast Cancer Survivors in an Asian Country: a Qualitative Study
This study aimed to understand the challenges in obtaining and seeking information among Malaysian breast cancer survivors. We conducted semi-structured, one-to-one interviews among patients using AET from two hospitals and a local cancer organization. Interviews were conducted until theme saturation was achieved (N = 25). Interviews were de-identified, transcribed verbatim, and analysed using thematic analysis. To ensure rigor, coding was conducted through regular discussions between two researchers and the findings were shared with several participants after analysis was completed. Three main themes were identified: limi...
Source: Journal of Cancer Education - March 26, 2024 Category: Cancer & Oncology Source Type: research
Patient-reported symptoms before adjuvant locoregional radiotherapy for breast cancer: triple-negative histology impacts the symptom burden
ConclusionDifferent surgical strategies, age, and body mass index did not impact on ESAS scores, while the type of adjuvant systemic therapy did. The effect of previous neoadjuvant treatment and unfavorable tumor biology (triple negative) emerged as important factors associated with symptom burden, albeit in different domains. ESAS data may facilitate identification of patients who should be considered for additional supportive measures to alleviate specific symptoms. (Source: Strahlentherapie und Onkologie)
Source: Strahlentherapie und Onkologie - March 26, 2024 Category: Cancer & Oncology Source Type: research
Heterochronous multiple primary prostate cancer and lymphoma: A case report
CONCLUSION: Although rare, the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding.PMID:38524523 | PMC:PMC10955537 | DOI:10.12998/wjcc.v12.i7.1333 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Jin-Long Liang Yu-Qing Bu Li-Li Peng Hong-Zhen Zhang Source Type: research
Heterochronous multiple primary prostate cancer and lymphoma: A case report
CONCLUSION: Although rare, the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding.PMID:38524523 | PMC:PMC10955537 | DOI:10.12998/wjcc.v12.i7.1333 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Jin-Long Liang Yu-Qing Bu Li-Li Peng Hong-Zhen Zhang Source Type: research
Heterochronous multiple primary prostate cancer and lymphoma: A case report
CONCLUSION: Although rare, the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding.PMID:38524523 | PMC:PMC10955537 | DOI:10.12998/wjcc.v12.i7.1333 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Jin-Long Liang Yu-Qing Bu Li-Li Peng Hong-Zhen Zhang Source Type: research
Heterochronous multiple primary prostate cancer and lymphoma: A case report
CONCLUSION: Although rare, the possibility of prostate cancer combined with a double primary cancer of DLBCL can provide a deeper understanding.PMID:38524523 | PMC:PMC10955537 | DOI:10.12998/wjcc.v12.i7.1333 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Jin-Long Liang Yu-Qing Bu Li-Li Peng Hong-Zhen Zhang Source Type: research
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports
ConclusionsWe observed two cases of recurrent severe hypocalcemia in patients with advanced breast cancer and bone metastases after modifications to their therapy regimens. These cases differed from the typical hypocalcemia induced by bone-modifying agents. It is possible that antitumor drugs affect calcium and bone metabolism associated with bone metastases. While these cases are rare, it is crucial for oncologists to be aware of hypocalcemia not only at the initiation of bone-modifying agents but also throughout the entire antitumor therapy, as hypocalcemia can lead to fatal outcomes. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - March 25, 2024 Category: General Medicine Source Type: research
A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice
ConclusionThis real-world US study showed that approximately two-thirds of 2L patients received subsequent therapy and disease progression was the most common reason for 2L discontinuation highlighting the need for timely 2L treatment with the most efficacious drug to allow patients to achieve longer treatment duration and delayed progression. (Source: International Journal of Clinical Oncology)
Source: International Journal of Clinical Oncology - March 25, 2024 Category: Cancer & Oncology Source Type: research
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
CONCLUSIONS: Our RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy.PMID:38519708 | DOI:10.1007/s12094-024-03399-3 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Helena Pla Eudald Felip Ver ónica Obadia Sonia Pernas Gemma Vi ñas Mireia Margel í Roser Fort-Culillas Sonia Del Barco Nuria Sabat é Eduard Fort Clara Lezcano Beatriz Cirauqui Vanesa Quiroga Agostina Stradella Miguel Gil Gil Anna Esteve Sabela Recalde Source Type: research
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
CONCLUSIONS: Our RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy.PMID:38519708 | DOI:10.1007/s12094-024-03399-3 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 23, 2024 Category: Cancer & Oncology Authors: Helena Pla Eudald Felip Ver ónica Obadia Sonia Pernas Gemma Vi ñas Mireia Margel í Roser Fort-Culillas Sonia Del Barco Nuria Sabat é Eduard Fort Clara Lezcano Beatriz Cirauqui Vanesa Quiroga Agostina Stradella Miguel Gil Gil Anna Esteve Sabela Recalde Source Type: research
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
ConclusionsOur RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 22, 2024 Category: Cancer & Oncology Source Type: research
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
CONCLUSION: The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.PMID:38513188 | DOI:10.1200/JCO.23.01940 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Erica L Mayer Yue Ren Nikhil Wagle Reshma Mahtani Cynthia Ma Angela DeMichele Massimo Cristofanilli Jane Meisel Kathy D Miller Yara Abdou Elizabeth C Riley Rubina Qamar Priyanka Sharma Sonya Reid Natalie Sinclair Meredith Faggen Caroline C Block Naomi Ko Source Type: research
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
CONCLUSION: The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.PMID:38513188 | DOI:10.1200/JCO.23.01940 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Erica L Mayer Yue Ren Nikhil Wagle Reshma Mahtani Cynthia Ma Angela DeMichele Massimo Cristofanilli Jane Meisel Kathy D Miller Yara Abdou Elizabeth C Riley Rubina Qamar Priyanka Sharma Sonya Reid Natalie Sinclair Meredith Faggen Caroline C Block Naomi Ko Source Type: research
